New FDA-Approved Treatment for RKD

The FDA has approved Gazyva® (obinutuzumab) for adults and children ages 2 and older with idiopathic nephrotic syndrome that began in childhood and is frequently relapsing (FRNS) or steroid-dependent (SDNS). More information coming soon. Please visit our Patient Navigation tool for support.

RESOURCES

/

FIND A SPECIALIST

/

CONTACT

Contact This Study

Sign up to get NephCure’s latest updates.

SIGN UP
This field is for validation purposes and should be left unchanged.